ES3027194T3 - Mutant bordetella strains and methods for use - Google Patents

Mutant bordetella strains and methods for use Download PDF

Info

Publication number
ES3027194T3
ES3027194T3 ES17715426T ES17715426T ES3027194T3 ES 3027194 T3 ES3027194 T3 ES 3027194T3 ES 17715426 T ES17715426 T ES 17715426T ES 17715426 T ES17715426 T ES 17715426T ES 3027194 T3 ES3027194 T3 ES 3027194T3
Authority
ES
Spain
Prior art keywords
pertactin
subject
deficient
composition
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17715426T
Other languages
English (en)
Spanish (es)
Inventor
Luis Solans
Camille Locht
Anne Tsicopoulos
Yahia Sendid Saliha Ait
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Institut Pasteur
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Institut Pasteur filed Critical Institut National de la Santé et de la Recherche Médicale
Application granted granted Critical
Publication of ES3027194T3 publication Critical patent/ES3027194T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
ES17715426T 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use Active ES3027194T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314843P 2016-03-29 2016-03-29
PCT/EP2017/057468 WO2017167834A1 (en) 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use

Publications (1)

Publication Number Publication Date
ES3027194T3 true ES3027194T3 (en) 2025-06-13

Family

ID=58488973

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17715426T Active ES3027194T3 (en) 2016-03-29 2017-03-29 Mutant bordetella strains and methods for use

Country Status (10)

Country Link
US (4) US10682377B2 (enExample)
EP (2) EP4541809A3 (enExample)
JP (1) JP6993984B2 (enExample)
CN (2) CN109069535B (enExample)
AU (2) AU2017242541B2 (enExample)
DK (1) DK3436034T3 (enExample)
ES (1) ES3027194T3 (enExample)
FI (1) FI3436034T3 (enExample)
SG (1) SG11201807783UA (enExample)
WO (1) WO2017167834A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104451A1 (en) * 2006-03-10 2007-09-20 Institut Pasteur De Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
CN102448490B (zh) 2009-04-28 2015-05-13 国家健康与医学研究院 用于预防或治疗过敏原引起的气道疾病的疫苗
US10682377B2 (en) * 2016-03-29 2020-06-16 Institut Pasteur De Lille Mutant Bordetella strains and methods of use
EP3697439A1 (en) 2017-10-18 2020-08-26 Institut Pasteur de Lille Bordetella strains expressing serotype 3 fimbriae
AU2021325149A1 (en) 2020-08-14 2023-03-02 ILiAD Biotechnologies, Inc. Lyophilized live bordetella vaccines
CN116635517A (zh) * 2020-11-17 2023-08-22 伊利亚德生物技术有限公司 与神经退行性疾病相关的神经病理的治疗和预防
KR20250038747A (ko) 2022-07-22 2025-03-19 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 만성 폐쇄성 폐질환의 치료를 위한 보르데텔라 균주의 용도
WO2025257397A1 (en) 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
FR2718750B1 (fr) 1994-04-19 1996-06-14 Pasteur Institut Protéines recombinantes de l'hémagglutinine filamenteuse de Bordetella, notamment, B. Pertussis, production et application à la production de protéines étrangères ou de principes actifs vaccinants.
DE69511392T2 (de) * 1994-04-28 2000-03-23 Takeda Chemical Industries, Ltd. Verfahren zur trennung von protektiven verbindungen aus bordetella pertussis
FR2754543B1 (fr) 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
FR2840319B1 (fr) 2002-05-30 2004-08-20 Pasteur Institut Souches de bordetella rendues deficientes par attenuation genetique
US7582297B2 (en) 2003-04-11 2009-09-01 Medimmune, Llc Methods of treating respiratory conditions
WO2007104451A1 (en) 2006-03-10 2007-09-20 Institut Pasteur De Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
US20100111996A1 (en) 2006-11-15 2010-05-06 Denis Leclerc Papaya Mosaic Virus-Based Vaccines for Influenza
CA2678698A1 (en) 2007-02-23 2008-10-02 The Penn State Research Foundation Use of an avirulent bordetella mutant as a live vaccine vector
AU2008266910A1 (en) 2007-06-18 2008-12-24 Hemispherx Biopharma, Inc. Early intervention of viral infections with immune activators
CN102448490B (zh) 2009-04-28 2015-05-13 国家健康与医学研究院 用于预防或治疗过敏原引起的气道疾病的疫苗
CA2765364C (en) 2009-06-15 2015-05-26 National University Of Singapore Influenza vaccine, composition, and methods of use
SG10201607233TA (en) * 2011-11-02 2016-10-28 Univ Singapore Effect of an attenuated bordetella strain against allergic disease
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
US10682377B2 (en) * 2016-03-29 2020-06-16 Institut Pasteur De Lille Mutant Bordetella strains and methods of use

Also Published As

Publication number Publication date
EP4541809A2 (en) 2025-04-23
US20200323901A1 (en) 2020-10-15
AU2022221438B2 (en) 2024-10-03
CN114767718A (zh) 2022-07-22
US10682377B2 (en) 2020-06-16
WO2017167834A1 (en) 2017-10-05
US20170283890A1 (en) 2017-10-05
CN109069535A (zh) 2018-12-21
SG11201807783UA (en) 2018-10-30
DK3436034T3 (da) 2025-05-12
JP2019513722A (ja) 2019-05-30
US11065276B2 (en) 2021-07-20
AU2017242541B2 (en) 2022-06-30
CA3018126A1 (en) 2017-10-05
FI3436034T3 (fi) 2025-05-08
JP6993984B2 (ja) 2022-02-03
EP4541809A3 (en) 2025-06-25
AU2022221438A1 (en) 2022-10-06
CN109069535B (zh) 2022-03-18
US20210290667A1 (en) 2021-09-23
US20230381224A1 (en) 2023-11-30
EP3436034A1 (en) 2019-02-06
AU2017242541A1 (en) 2018-10-11
EP3436034B1 (en) 2025-03-26

Similar Documents

Publication Publication Date Title
US11065276B2 (en) Mutant Bordetella strains and methods of use
Solans et al. IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine
Solans et al. The role of mucosal immunity in pertussis
US12403188B2 (en) Bordetella strains expressing serotype 3 fimbriae
JP2004536106A (ja) マイコプラズマ・ボビスワクチンおよび動物の肺炎を減少させる方法
DK2453913T3 (en) Temperature sensitive vaccine strain of Mycoplasma hyopneumoniae and uses thereof
JP2019513722A5 (enExample)
Stasiłojć et al. Recombinant Bacillus subtilis spores elicit Th1/Th17-polarized immune response in a murine model of Helicobacter pylori vaccination
JP2005112865A (ja) 百日咳菌ワクチン用アジュバントとしてのｉｌ−１２
He et al. Vaccination with a Brucella ghost developed through a double inactivation strategy provides protection in Guinea pigs and cattle
WO2020049133A1 (en) Adenylate cyclase catalytic domain deficient bordetella strains
Mann et al. Use of a genetically defined double mutant strain of Bordetella bronchiseptica lacking adenylate cyclase and type III secretion as a live vaccine
CA3018126C (en) Mutant bordetella strains and methods of use
HK1262896B (en) Mutant bordetella strains and methods for use
HK1262896A1 (en) Mutant bordetella strains and methods for use
HK40115864A (en) Bordetella strains expressing serotype 3 fimbriae
HK40026630B (en) Bordetella strains expressing serotype 3 fimbriae
Pilione et al. Use of a Genetically Defined Double Mutant